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Aims of the study: To analyse the coping strategies of patients 
suffering from hip and knee osteoarthritis (OA) by defining the 
factors determining these strategies, and to study the psychome- 
tric qualities of the French version of the PCI (pain coping inven- 
tory) questionnaire [1] for OA. 
Patients and Methods: In a national cross-sectional survey 1811 
GPs included 5324 patients suffering from hip and knee OA. The 
questionnaires were filled in by the patients and were analysed for 
correlations between specific PCI domains and patient's demo- 
graphic characteristics, clinical variables, pain and priority handi- 
cap as defined by the patient. 
Results: The questionnaires of 4598 patients (86.4%) were anal- 
ysed. 
Structure of the PCI questionnaire: Factor analysis showed that 
the 33 PCI questionnaire items could be grouped into six previ- 
ously described domains and that the PCI had a good structural 
validity. The scores of each of the six domainsfor the 4588 OA pa- 
tients were: pain transformation 1.94-0.6; distraction 1.94-0.6; re- 
ducing demands 2.44-0.6; retreating 1.74-0.6; worrying 2.04--0.6; 
resting 2.54-0.7. For all patients, the passive and active coping 
scores were the same: 2.14-0.4 and 2.14--0.5, respectively. Ac- 
tive coping strategies consisted mostly of reducing demands and 
passive coping strategies consisted mostly of resting. 
- Differences in coping depending on the location of osteoarthri- 
tis: PCI scores were higher for patients having both knee and 
hip involvement compared to patients with only one location. The 
coping strategies were not different with respect to the location of 
OA, but patients with hip osteoarthritis expressed more difficulties 
for resting. 
- Differences in coping depending on sex, age and weight: Sig- 
nificant differences in four of the six domains of the PCI were 
found for sex aand age. Passive domain scores were significantly 
higher for women, older patients and overweight patients. There 
was a significant difference in coping strategies (p<0.001) be- 
tween men and women, with more passive coping for women. 
- Differences in coping according to the type of priority handi- 
cap: When patients expressed their priority handicap on being on 
daily living and social activities, passive coping strategies were 
more important, mostly resting. Active coping strategies were 
more important for patients when the priority handicap was on 
sport, leisure and outdoor activities. 
Conclusions: The PCI questionnaire has a good structural va- 
lidity, with six well-defined omains. It showed that there are sig- 
nificant differences in the coping strategies of patients with lower 
limb OA, according sex, age and weight. It showed that coping 
strategies are influenced by the priority handicap with which the 
patients felt they were affected. 
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IA HA therapy is indicated for the treatment (Rx) of pain of knee 
osteoarthritis (OA). Based on results of several small studies, we 
chose to evaluate the potential benefits of IA HA for shoulder 
pain. 
Design: DB, randomized, saline-controlled, 6-mo study in pa- 
tients with chronic shoulder pain: either sex, _>35 yrs of age, with 
moderate-to-severe unilateral shoulder pain (>0.5, <5 yrs) due to 
(exam, x-ray, MRI) glenohumeral joint OA, rotator cuff tear (RCT), 
and/or adhesive capsulitis. On admission, patients had limited 
range of motion (ROM) and failed to respond adequately to phys- 
ical therapy, _>1 steroid injection, and analgesics. Patients were 
stratified into OA (4- additional pathologies) and Non-OA. There 
were 3 Rx groups: 5 weekly IA saline (PBS); 5 weekly IA HA (HA- 
5); or 3 weekly IA HA followed by 2 weekly IA PBS (HA-3). Pri- 
mary efficacy outcome in the intent-to-treat (ITT) population was 
shoulder pain on movement (100-mm visual analog scale, VAS) 
at 3 mos. Some secondary endpoints included night pain, ROM, 
and SF-12. 
Results: For all groups-average age 63 yrs, 37% BMI >30.5, and 
50% male. 61% had OA, 2/3 of whom also had RCT (55% partial). 
For the ITT population (n=602), the overall Rx effect on pain re- 
duction was significant for HA-3 (p=0.036) and HA-5 (p=0.012) vs 
control over 6 mos using a mixed-effect model. At individual time- 
points, significant improvements were seen for the HA-3 group at 
Wks 17 (p=0.025) and 26 (p=0.005) and for the HA-5 group at 
Weeks 7 (p=0.011) and 17 (p=0.001). The HA groups were not 
statistically different from each other. The majority of benefit was 
seen in OA patients. In OA patients at 3 mos, pain reduction with 
HA-3 (p=0.051) and HA-5 (p=0.058) vs control, and the overall 
treatment effect through 6 mos was statistically significant (HA- 
3: p=0.003 and HA-5: 0.002). The HA-50A group demonstrated 
significant pain reduction at Wks 7 (p=0.001), 9 (p=0.018), 17 
(p=0.006), and 26 (p=0.020), and the HA-3 group exhibited sig- 
nificant pain reduction at Weeks 17 (p=0.012) and 26 (p=<0.001). 
In contrast, neither Non-OA HA group differed significantly from 
control at 3 mos or in 6-mos overall Rx effect. Secondary out- 
come measures tended to support the primary outcome. The 
safety profile was favorable in all groups, with no significant dif- 
ferences observed between groups in adverse event profile and 
a low incidence (<1%) of injection-site pain. 
Conclusion: The results demonstrate that HA-3 or HA-5 injec- 
tions are efficacious for the Rx of chronic shoulder pain due to 
OA alone or associated with multiple etiologies, even in patients 
refractory to standard-of-care, nonsurgical interventions. HA ther- 
apy was well tolerated in this elderly population. 
